Skip to main content

February 2012 Vol 5, No 1, Special Issue

First Cost Analysis of Long-Term Management of CML
Neil Canavan, Neil Canavan
Read More
Graft-versus-Host Disease Often Leads to Posttransplant Readmission, High Costs
Read More
Is Plerixafor Cost-Effective for Stem-Cell Mobilization?
Caroline Helwick, Caroline Helwick
Read More
Leukemia, Oncology
Bosutinib Shows Superior Results in CML
Neil Canavan, Neil Canavan
Read More
Leukemia, Oncology
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
Caroline Helwick, Caroline Helwick, Caroline Helwick
Read More
Multiple Myeloma, Multiple Myeloma, Oncology
VISTA Final Analysis Upholds Survival Benefit of Bortezomib at 5 Years
Caroline Helwick, Caroline Helwick
Read More
Multiple Myeloma, Multiple Myeloma, Oncology
Maintenance Strategies in Elderly Patients with Myeloma Not Eligible for Transplant
Caroline Helwick, Caroline Helwick
Read More
Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs
Caroline Helwick, Caroline Helwick
Read More
Conference Highlights ASH
Ready-Made Platelets? A Boon for Patients If It Works
Neil Canavan, Neil Canavan
Read More
Cost of Treating Myeloproliferative Neoplasms Is Significant
Neil Canavan, Neil Canavan
Read More
Page 1 of 3
Results 1 - 10 of 29